The sponsor identified 3 economic studies, all in UK settings. Taylor et al. (2009) carried out a cost-effectiveness analysis on non-union tibial fractures treated by EXOGEN or by surgery ...
August 4, 2006 — The US Food and Drug Administration (FDA) has approved a bone healing system that accelerates the time to healing in fresh, closed, posteriorly displaced distal radius fractures and ...
SAN FRANCISCO (MarketWatch) -- Smith & Nephew's Plc's orthopaedic trauma & clinical therapies division said Tuesday the Food and Drug Administration has approved its Exogen 4000+ bone healing system.
The new EXOGEN, which replaces the previous EXOGEN 4000+ model, is portable and more user friendly, with its new color LCD screen, splash-proof casing, and sleeker, lightweight design; and more ...
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...